Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference
SUMMIT, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients with prolonged focal, generalized or cluster epileptic seizure episodes, will participate in the 21st Annual H.C. Wainwright Global Investment Conference this week in New York City.
Gregory T. Mayes, President and CEO of Engage Therapeutics, will present a company overview on Tuesday, Sept. 10, at 5:05 p.m. ET, at the conference.
About Engage Therapeutics, Inc.Engage Therapeutics is developing Staccato alprazolam for the immediate cessation of active and acute epileptic seizures. The investigational product, which is in the Rapid Epileptic Seizure Termination (REST) category of products, is being evaluated in a phase 2b clinical trial for the treatment of patients with epilepsy. Staccato alprazolam is a single-use, investigational epileptic seizure rescue therapy that combines the Staccato delivery technology, which is currently used in a U.S. Food and Drug Administration (FDA) approved product, with alprazolam, an FDA-approved benzodiazepine. It is a small, easy-to-use, hand-held inhaler that delivers alprazolam with a single breath, potentially providing a way for people with epilepsy and their caregivers to stop an ongoing seizure. The Staccato system rapidly vaporizes alprazolam to form aerosol, with particle size designed for deep lung delivery, producing a rapid, systemic effect. In a phase 2a proof-of-concept study, Staccato alprazolam demonstrated rapid reduction of seizure-like activity in a photosensitivity model.
Engage Therapeutics is based in Summit, N.J. For additional information, please see www.engagetherapeutics.com.